The role of antibodies in HIV vaccines.

Published

Journal Article (Review)

Licensed vaccines against viral diseases generate antibodies that neutralize the infecting virus and protect against infection or disease. Similarly, an effective vaccine against HIV-1 will likely need to induce antibodies that prevent initial infection of host cells or that limit early events of viral dissemination. Such antibodies must target the surface envelope glycoproteins of HIV-1, which are highly variable in sequence and structure. The first subunit vaccines to enter clinical trails were safe and immunogenic but unable to elicit antibodies that neutralized most circulating strains of HIV-1. However, potent virus neutralizing antibodies (NAbs) can develop during the course of HIV-1 infection, and this is the type of antibody response that researchers seek to generate with a vaccine. Thus, current vaccine design efforts have focused on a more detailed understanding of these broadly neutralizing antibodies and their epitopes to inform the design of improved vaccines.

Full Text

Duke Authors

Cited Authors

  • Mascola, JR; Montefiori, DC

Published Date

  • January 2010

Published In

Volume / Issue

  • 28 /

Start / End Page

  • 413 - 444

PubMed ID

  • 20192810

Pubmed Central ID

  • 20192810

Electronic International Standard Serial Number (EISSN)

  • 1545-3278

International Standard Serial Number (ISSN)

  • 0732-0582

Digital Object Identifier (DOI)

  • 10.1146/annurev-immunol-030409-101256

Language

  • eng